NCT00607750View on ClinicalTrials.gov

Safety and Efficacy of ATG003 in Patients With AMD Receiving Anti-VEGF

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

April 30, 2010

Study Completion Date

May 31, 2010

Conditions
Age-Related Macular Degeneration
Interventions
DRUG

ATG003 (mecamylamine)

1% Ophthalmic solution, eyedrop BID, 48 weeks

DRUG

Placebo

Placebo eyedrops, BID, 48 weeks

Sponsors

Lead Sponsor

CoMentis
All Listed Sponsors
lead

CoMentis

INDUSTRY